Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 14/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21772947 | 1.00 | MELK (0.37) | MELKIRAK4PIM1CCNB2CDK1 | |
| SCHEMBL21788972 | 0.81 | MELK (0.45) | MELKADORA1 | |
| SCHEMBL21788758 | 0.81 | MELK (0.45) | MELKCDK7CDK9 | |
| SCHEMBL21788756 | 0.80 | MELK (0.36) | MELKIRAK4CCNB2CDK1CCNB1 | |
| SCHEMBL21788760 | 0.79 | TYRO3 (0.41) | MELKPIM1CCNB2CDK1CCNB1 | |
| SCHEMBL21788954 | 0.79 | IRAK1 (0.46) | IRAK4PIM1 | |
| SCHEMBL21788747 | 0.79 | MERTK (0.50) | MELKIRAK4PIM1CCNB2CDK1 | |
| SCHEMBL21788757 | 0.79 | TYRO3 (0.40) | MELKIRAK4CCNB2CDK1CCNB1 | |
| SCHEMBL21788755 | 0.79 | TYRO3 (0.42) | MELKIRAK4CCNB2CDK1CCNB1 | |
| SCHEMBL21788963 | 0.79 | TYRO3 (0.42) | MELKCCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | MELK 271/4885IRAK4 345/4885PIM1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.